ChatGPT for Clinicians Launched. UK Doctors Are Excluded.

On 23 April 2026, OpenAI launched ChatGPT for Clinicians. Two days later, OpenEvidence — the tool it most closely resembles — withdrew from the UK entirely.

UK doctors received both announcements in the same week. Neither had good news for them.

What ChatGPT for Clinicians actually does

ChatGPT for Clinicians is OpenAI's attempt to bring its AI capabilities directly into clinical practice. It answers clinical questions with cited, peer-reviewed sources. Think point-of-care decision support — you ask a question, it returns a synthesised answer grounded in the medical literature.

It is, in substance, a more powerful version of what OpenEvidence was doing. And like OpenEvidence, it is currently unavailable to UK and EEA clinicians.

The exclusion is not subtle. UK doctors navigating to the product are met with a "not available in your region" message.

Why the UK is locked out

The most likely explanation is regulatory caution.

The EU AI Act classifies certain clinical AI tools as high-risk systems, with corresponding requirements around transparency, conformity assessment, and liability. The UK's own AI regulatory framework — post-Brexit and currently being shaped through the AI Opportunities Action Plan — remains unsettled. For US companies launching regulated healthcare AI products, the safest short-term decision is often to restrict access to markets where the regulatory path is clear.

The US is one of those markets. The UK currently is not.

This is the same logic that drove OpenEvidence's withdrawal. It is also the reason that UpToDate Pro Plus AI — launched with much fanfare in early 2026 — remains US and Canada only.

UK doctors are not being forgotten. They are being deliberately excluded while the regulatory picture clears.

The pattern UK clinicians should know about

In the space of a fortnight, two of the most prominent AI clinical tools in the world became unavailable to UK doctors:

23 April 2026: ChatGPT for Clinicians launches. UK and EEA excluded.
25 April 2026: OpenEvidence withdraws from the UK and EU.

Both tools were primarily Q&A products — you bring a clinical question, they return a referenced answer. That specific use case now has a meaningful gap in the UK market.

For clinical Q&A: what's available in the UK

iatroX is UK-based, holds MHRA registration and UKCA marking, and is actively positioning as the UK alternative for AI clinical Q&A. It does the same job as OpenEvidence and ChatGPT for Clinicians — referenced answers to point-of-care questions — within a UK regulatory framework.

It is not a perfect substitute. These tools differ in model quality, citation depth, and interface. But it is the most credible UK-regulatory-compliant option in this space right now.

The other half of the problem

Clinical Q&A tools solve a specific problem: you have a question, you need a referenced answer, you get one quickly.

What they do not solve — and what is easy to overlook in the noise around these launches and withdrawals — is the problem of staying current.

A practice-changing trial published last week does not appear in any Q&A tool until you already know to ask about it. The gap between what was published and what you know exists, whether or not ChatGPT for Clinicians is available in your region.

That is the problem we built The Monday Clinical Brief to address.

What The Monday Clinical Brief offers

Every Monday morning, we send you the five most important peer-reviewed papers published in your specialty that week. Plain-language summaries. Links to the originals. Nothing else.

We cover 31 specialties. We do the curation. You stay current.

£20 a year. No app. No regulatory uncertainty. Just your inbox.

Subscribe to The Monday Clinical Brief — and know what's new before anyone asks you about it.

The bottom line

ChatGPT for Clinicians is not coming to the UK any time soon. Neither, for now, is OpenEvidence. For clinical Q&A in the meantime, iatroX is the most credible UK option.

But neither of those tools — available or not — tells you what was published last week. That is a different job. And it matters just as much.

Frequently Asked Questions

What is ChatGPT for Clinicians?

ChatGPT for Clinicians is an OpenAI product launched on 23 April 2026. It provides AI-assisted clinical decision support with cited, peer-reviewed sources — similar in concept to OpenEvidence. It is currently only available to clinicians in the United States.

Why is ChatGPT for Clinicians not available in the UK?

OpenAI has not made ChatGPT for Clinicians available in the UK or EEA. The likely reason is regulatory uncertainty around AI in healthcare — the EU AI Act classifies certain clinical AI tools as high-risk, and the UK's own AI regulatory framework remains unsettled. Several US AI health tools have paused or withdrawn UK access for the same reason.

What can UK doctors use instead of ChatGPT for Clinicians?

For clinical Q&A at the point of care, iatroX is a UK-based alternative with MHRA registration and UKCA marking. For staying current with the medical literature — knowing what's new in your specialty each week — The Monday Clinical Brief is a weekly digest covering 31 specialties for £20 a year.

Did OpenEvidence also leave the UK?

Yes. OpenEvidence withdrew from the UK and EU on 25 April 2026 — two days after ChatGPT for Clinicians launched and excluded UK users. UK doctors lost both tools in the same fortnight.

Stay on top of the evidence

Weekly journal digests for 31 medical specialties. Structured summaries, every Monday.

Start your free trial →